Autopsy report · NCT01495572
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Cause of deathSlow enrollment
“Due to slow accrual, the investigator decided to close the study.”
Life of this trial
- Ran for about 2 years 2 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Metastatic Melanoma; Skin Cancer
- Interventions
- Fludarabine; Cyclophosphamide; Aldesleukin; MART-1 Reactive CD8+ PBL
- Participants
- 5
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis
“Due to the principal investigator leaving the institution and slow enrollment, we have decided to close the study prior to study completion” - Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
“accrual was slow and sporadic so the study was closed” - A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
“The applicant decided to close the study” - L-Menthol Injection as a Novel Technique During Colonoscopy
“Sponsor/Investigator has decided to close out the study” - Intensive Lifestyle Intervention in Patients With Insulin-treated Type 2 Diabetes: a Pilot Project
“Recruitment was difficult, and the investigator decided to close the study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.